Anne H. C. Valk

Anne H. C. Valk

Auto-generated profile, based on publicly available information

Anne H. C. Valk

Laboratory of Radiotherapy & OncoImmunology, Department of Radiation Oncology, Radboud Institute for Medical Innovation

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2021 in Magnetic Resonance in Medicine
Verified
Journal Article
Open access
PDF file
AVAnne Valk
Anne Valk
CWCorin Willers
Corin Willers
KSKamal Shahim
Kamal Shahim
OPOrso Pusterla
Orso Pusterla
GBGrzegorz Bauman
Grzegorz Bauman
PLPhilipp Latzin
Philipp Latzin
Purpose: Lung impairment from functional MRI is frequently assessed as defect percentage. The defect distribution, however, is currently not quantified. The purpose of this work was to develop a novel measure that quantifies how clustered or scattered defects in functional lung MRI appear, and to evaluate it in pediatric cystic fibrosis.Theory: The defect distribution index (DDI) calculates a score for each lung voxel categorized as defected. The index increases according to how densely and how far an expanding circle around a defect voxel contains more than 50% defect voxels.Methods: Fractional ventilation and perfusion maps of 53 children with cystic fibrosis were previously acquired with matrix pencil decomposition MRI. In this work, the DDI is compared to a visual score of 3 raters who evaluated how clustered the lung defects appear. Further, spearman correlations between DDI and lung function parameters were determined.Results: The DDI strongly correlates with the visual scoring (r = 0.90 for ventilation; r = 0.88 for perfusion; P < .0001). Although correlations between DDI and defect percentage are moderate to strong (r = 0.61 for ventilation; r = 0.75 for perfusion; P < .0001), the DDI distinguishes between patients with comparable defect percentage.Conclusion: The DDI is a novel measure for functional lung MRI. It provides complementary information to the defect percentage because the DDI assesses defect distribution rather than defect size. The DDI is applicable to matrix pencil MRI data of cystic fibrosis patients and shows very good agreement with human perception of defect distributions.

6 September 2024 in Clinical & Translational Immunology
Verified
Journal Article
Open access
EHEline Jh van Houtum
Eline Jh van Houtum
AVAnne Hc Valk
Anne Hc Valk
DGDaniel Granado
Daniel Granado
JLJasper Lok
Jasper Lok
LBLune van Den Bogaard
Lune van Den Bogaard
GAGosse J. Adema
Gosse J. Adema
Objectives: PD‐1/PD‐L1 immune checkpoint blockade can be an effective treatment for advanced breast cancer patients. However, patients with oestrogen receptor positive (ER+) tumors often display only low lymphocyte infiltration, while a large part of triple negative (TN) breast tumors does not generate an effective immunotherapy response. Therefore, new treatment strategies have to be developed. Here, we investigate Siglec‐7 and Siglec‐9 as novel ITIM‐bearing inhibitory immune checkpoint receptors similar to PD‐1, but expressed on a broader range of immune cells.Methods: We assessed Siglec‐7 and Siglec‐9 (ligand) expression in TN and ER+ breast cancer tumors and their breast cancer cell line‐induced signalling.Results: We report that Siglec‐7 and Siglec‐9 are highly expressed in TN tumors, and to a low extent in ER+ tumors. Siglec‐7 was observed on myeloid cells, T cells, and NK cells and Siglec‐9 preferentially on myeloid cells. Expression of sialoglycans, including Siglec‐7 and Siglec‐9 ligands, was observed in both TN and ER+ breast cancer tissue sections. Expression levels of Siglec‐7 and Siglec‐9 ligands were higher on in vitro cultured TN cell lines than ER+ cell lines. Importantly, by applying chimeric Siglec‐7 reporter cells, we showed the induction of Siglec‐7 signalling by multiple TN cell lines, but only by one ER+ cell line. Moreover, Siglec‐7 signalling is directly related to Siglec‐7 ligand expression levels of breast cancer cell lines.Conclusion: These data imply that immunotherapy targeting Siglec receptors may be particularly interesting for TN breast cancer patients not responding to current treatment strategies with tumors displaying high immune cell infiltration.

2 April 2026 in OncoImmunology
Verified
Journal Article
Open access
JSJesper van Eck van der Sluijs
Jesper van Eck van der Sluijs
AVAnne H. C. Valk
Anne H. C. Valk
EHEline J. H. van Houtum
Eline J. H. van Houtum
EKEsther D. Kers-Rebel
Esther D. Kers-Rebel
MLMaaike Looman
Maaike Looman
GAGosse J. Adema
Gosse J. Adema
The development of effective cancer immunotherapies has received significant attention in recent years. However, the immunosuppressive tumor microenvironment (TME) hampers the efficacy of cancer im...

29 October 2026 in OncoImmunology
Verified
Journal Article
Open access
AVAnne H.C. Valk
Anne H.C. Valk
MBMatthia G.M. Boros
Matthia G.M. Boros
FSFabian Schuurmans
Fabian Schuurmans
GAGosse J. Adema
Gosse J. Adema
LCLenneke Cornelissen
Lenneke Cornelissen
Sialoglycans, carbohydrate structures terminated by negatively charged sialic acid residues, are expressed on the surface of virtually all mammalian cells. They are a crucial part of the glycocalyx...